JAK inhibitors in rheumatoid arthritis-associated interstitial lung disease: a review of mechanisms and clinical evidence
Janus kinase (JAK) inhibitors, as oral targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs), represent a promising therapeutic option for rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Preclinical studies suggest a du…